title: New Approaches to Antibiotic Use and Review of Recently Approved Antimicrobial Agents.
abstract: Antimicrobial drug-resistance continues to force adaptation in our clinical practice. We explore new evidence regarding adjunctive antibiotic therapy for skin and soft tissue abscesses as well as duration of therapy for intra-abdominal abscesses. As new evidence refines optimal practice, it is essential to support clinicians in adopting practice patterns concordant with evidence-based guidelines. We review a simple approach that can 'nudge' clinicians towards concordant practices. Finally, the use of novel antimicrobials will play an increasingly important role in contemporary therapy. We review five new antimicrobials recently FDA-approved for use in drug-resistant infections: dalbavancin, oritavancin, ceftaroline, ceftolozane-tazobactam, and ceftazidime-avibactam.
authors.affiliation: Division of Infectious Diseases, University of Washington School of Medicine, 1959 Northeast Pacific Street, Seattle, WA 98195, USA. Electronic address: ahahn47@uw.edu.
authors.forename: Andrew W
authors.initials: AW
authors.lastname: Hahn
authors.affiliation: University of Washington School of Pharmacy, 1959 Northeast Pacific Street, Seattle, WA 98195, USA.
authors.forename: Rupali
authors.initials: R
authors.lastname: Jain
authors.affiliation: Division of Infectious Diseases, University of Washington School of Medicine, 1959 Northeast Pacific Street, Seattle, WA 98195, USA.
authors.forename: David H
authors.initials: DH
authors.lastname: Spach
mesh_terms: D018784:Abdominal Abscess / Q000188:drug therapy; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001424:Bacterial Infections / Q000188:drug therapy*; D002511:Cephalosporins / Q000627:therapeutic use; D004334:Drug Administration Schedule; D017277:Drug Approval; D004338:Drug Combinations; D004352:Drug Resistance, Microbial; D006020:Glycopeptides / Q000627:therapeutic use; D006801:Humans; D000077427:Lipoglycopeptides; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D018461:Soft Tissue Infections / Q000188:drug therapy; D017334:Teicoplanin / Q000031:analogs & derivatives / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration; D000097583:Ceftaroline; D014640:Vancomycin / Q000031:analogs & derivatives
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D004338:Drug Combinations; D006020:Glycopeptides; D000077427:Lipoglycopeptides; D017334:Teicoplanin; D000097583:Ceftaroline; C469289:dalbavancin; C100708:oritavancin; D014640:Vancomycin
keywords: Antimicrobial resistance; Ceftaroline fosamil; Ceftazidime-avibactam; Ceftolozane-tazobactam; Dalbavancin; Intraabdominal abscess; Oritavancin; Soft tissue abscess